Treatment of children with chronic hepatitis B infection shortens the time to seroconversion, but whether this affords a long-term benefit remains uncertain, say researchers from Canada.
None of the children (of 164 in the study) had hepatocellular carcinoma at baseline or developed HCC during the follow-up period that averaged 4.9 years, the authors report.
Six of the children were anti-HBe positive, and the remaining 168 were HBeAg positive. Seventy of the latter (40.2%) seroconverted to anti-HBe-positive status during the study, the report indicates, with seroconversion rates being higher among children treated with lamivudine or interferon-alpha (19/27, 70.4%) than among untreated children (51/147, 34.7%).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!